Compare Alcon AG (ALC) vs iShares JPMorgan USD Emerging Markets Bond ETF (EMB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs iShares JPMorgan USD Emerging Markets Bond ETF — how do they compare? Alcon AG trades at $66.88 (market cap $32.69B), while iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.69. The key difference: Alcon AG pays a 0.54% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none, and iShares JPMorgan USD Emerging Markets Bond ETF is trading nearer its 52-week high, Alcon AG nearer its low. Which is the better fit depends on your goals.
| ALC | EMB | |
|---|---|---|
Market Cap | $32.69B | — |
Sector | Health | Fixed Income |
52-Week High | $92.22 | $97.74 |
52-Week Low | $62.02 | $91.52 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
EMB trades at $96.35, showing minimal daily movement with a 0.16% gain. The technical outlook is neutral, supported by a bullish moving average signal but offset by neutral oscillators and sell signals from the ADX. Recent corporate actions include scheduled dividend payments in 2026, though key financial ratios are unavailable for fundamental assessment.
The outlook for EMB hinges on emerging market bond dynamics and Federal Reserve policy, with news highlighting yield appeal but also sovereign default risks. Key risks include geopolitical tensions and inflation, while institutional interest in EM bond ETFs suggests underlying demand. Investors should weigh high-yield potential against macroeconomic volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →
